Stockreport

PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio’s Drop-Less Sustained-Release Ocular Therapy

PainReform Ltd. - Ordinary Shares  (PRFX) 
PDF TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) today announced, through its pharmaceutical division, the commencement of its develo [Read more]